We report the application of our proposed tool on a large dataset (n = 2,081 patients) and show that, in comparison to Ki67 scoring, the Ki67CL score can risk stratify luminal BC patients more significantly and adds more information above other clinicopathological features. This evidence concerns the gene MKI67 and breast cancer.